Phase 4 N=10 Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
Attention-Deficit/Hyperactivity Disorder
Primary: Cmax — 8.07; 10.09; 15.45 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=122 Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days — 57; 29 Participants — p=0.7186
Phase 3 N=399 Anti-VEGF Treatment for Prevention of PDR/DME
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Development of PDR and/or DME (Whichever Came First) — 27; 75 Eyes
Phase 3 N=164 Imaging of Coronary Plaques in Participants Treated With Evolocumab
Coronary Artery Disease (CAD)
Primary: Absolute Change From Baseline in Minimum FCT — 21.5; 42.7 µm — p=0.015
Phase 2 N=147 Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
Lupus Nephritis
Primary: Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR) — 0.326; 0.285; 0.305; 0.296 milligram/milligram (mg/mg) — p=0.9052
Phase 3 N=83 TBI Dose De-escalation for Fanconi Anemia
Fanconi Anemia
Primary: Number of Participant With Neutrophil Recovery — 78 Participants
Phase 2 N=85 A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
Neoplasms, Brain
Primary: Incidence of Treatment Emergent Adverse Events (AEs) in Part 1 (Dose Escalation) — 0; 0; 0; 1 Participants
N/A N=50 Deep-Learning Image Reconstruction in CCTA
Coronary Artery Disease
Primary: Subjective Image Quality — 5; 5 Score on a Likert scale (0-5) 5=best
Phase 4 N=562 AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
Post-Operative Atrial Fibrillation
Primary: Number of Perioperative Complications Associated With AtriClip Placement — 0 perioperative complications reported
N/A N=146 Imaging Guided Patient Selection for Interventional Revascularization Therapy
Acute Ischemic Stroke
Primary: Functional Outcome as Defined by a mRS of 0-2 at 90 Days Post-procedure — 57 Participants
N/A N=110 InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study
Overactive Bladder · Urinary Urge Incontinence · Urgency-frequency Syndrome
Primary: Motor or Sensory Response(s) During Lead Placement - by Subject — 107; 109; 3; 1 Participants
N/A N=529 Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
Infant, Newborn · Infant, Low Birth Weight · Infant, Small for Gestational Age
Primary: Death or Neurodevelopmental Impairment (NDI) — 44; 46; 27; 28 Participants — p=0.03
Phase 2 N=340 Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary: Part A: Danvatirsen With Durvalumab MTDs (Maximum Tolerated Dose) or Recommended Doses for Dose-expansion — 2; 3; 3; 2 mg/kg
N/A N=38 Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)
Obesity · Weight Loss · CHD - Coronary Heart Disease
Primary: Feasibility - Number of Enrolled Participants — 38 Participants
Phase 2 N=307 Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Refractory Diffuse Large B Cell Lymphoma (DLBCL) · Relapsed Diffuse Large B-Cell Lymphoma · Transformed Follicular Lymphoma (TFL)
Primary: Phase 1 Study: Number of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs) — 1 Participants